Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)

British Journal of Ophthalmology

Volumn 93, Issue 4, 2009, Pages 457-462

  Georgopoulos, M ^a   Polak, K ^a   Prager, F ^a   Prunte C ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; APREDNISOLON; BEVACIZUMAB; CEFTAZIDIME; CORTISONE; DEXAMETHASONE; FLOAL; LOMEFLOXACIN; OFLOXACIN; OKAZIN; PREDNISOLONE; PREDNISOLONE PIVALATE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HYPOPYON; IRIDOCYCLITIS; MALE; PRIORITY JOURNAL; RETINA GYRATE ATROPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL ACUITY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; ENDOPHTHALMITIS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VISUAL ACUITY; VITREOUS BODY;

EID: 64849085452     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.138479     Document Type: Article

References (19)

1. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:642e1-4.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8.
4. Pieramici DJ, Avery RL. Ranibizumab: treatment in patients with neovascular agerelated macular degeneration. Expert Opin Biol Ther 2006;6:1237-45.
5. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
6. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol 2006;124:1478-9.
7. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72e5.
8. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-50.
9. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
10. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-81.
11. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(5 Suppl):3-19S.
12. Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 2004;24:699-705.
13. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-98.
14. Pieramici DJ, Avery RL, Castellarin AA, et al. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006;26:841-2.
15. Aggio FB, Farah ME, de Melo GB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007;21:408-9.
16. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
17. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-9e1.
18. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
19. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.